Zydus receives USFDA tentative approval Valbenazine Capsules

20 Oct 2022 , 01:33 AM

Zydus Lifesciences subsidiary Zydus Worldwide DMCC has received tentative approval from the United States Food and Drug Administration USFDA to market Valbenazine Capsules USP 40 mg 60 mg and 80 mg USRLD Ingrezza Valbenazine Capsules are indicated for the treatment of adults with tardive dyskinesia movements in the face tongue or other body parts that cannot be controlled The drug will be manufactured at the groups formulation manufacturing facility at Ahmedabad SEZ India